InSysBio to take part in ACoP11

events
Conference
September 16, 2020

September 16, 2020

InSysBio announces its participation in Eleventh American Conference on Pharmacometrics (ACoP11) which is to be held in virtual format this year due to COVID-19 spread 9-13 November, 2020. The theme of ACoP11 is “Scaling New Heights.” InSysBio team is going to present 9 posters in frames of the Conference, namely:

Tuesday, November 10:

  • TUE-003 “Stimulation of erythropoiesis with ESA or blood donation: QSP model” by Alexander Stepanov, Galina Lebedeva
  • TUE-049 “Quantitative mechanistic model for amyloid beta and tau protein role in synaptic plasticity” by Stepan Lerner, Tatiana Karelina

Wednesday, November 11:

  • WED-027 “Application of different approaches to generate virtual patient populations for QSP model of Erythropoiesis” by Galina Kolesova, Oleg Demin, Alexander Stepanov
  • WED-034 “Practical Identifiability Analysis of QSP Models with LikelihoodProfiler” by Ivan Borisov, Evgeny Metelkin
  • WED-061 “Semi-mechanistic PK/RO modeling of anti-CD47 therapeutic agents” by Elena Vasileva1,2, Oleg Demin Jr2

Affiliation: 1 Lomonosov Moscow State University, Moscow, Russia; 2InSysBio, Moscow, Russia

Thursday, November 12:

  • THU-023 ““Heta compiler” is a framework for the development and management of Quantitative Systems Pharmacology modeling platforms” by Evgeny Metelkin
  • THU-078 “Monoclonal antibody therapy efficacy can be boosted by combinations with other treatments: predictions from integrated Alzheimer’s disease QSP platform” by Tatiana Karelina, Stepan Lerner
  • THU-082 “Unified approach for in vitro data based parameters estimation” by Veronika Musatova, Oleg Demin, Svetlana Rubina
  • THU-085 “CYTOCON as a tool to collect, compare and visualize available data on cells and cytokine concentrations in humans” by Vlad Leonov, Ekaterina Mogilevskaia, Elita Gerasimuk, Nail Gizzatkulov, Oleg Demin

We are looking forward to seeing again in person next year!

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

April 2022
MoTuWeThFrSaSu
    
1
2
3
4
1. 04 Apr 2022 11:02 InSysBio to participate in Quantitative Systems Pharmacology for Immuno-Oncology InSysBio announces its participation in Quantitative Systems Pharmacology for Immuno-Oncology, a joint meeting of the EMBL's European Bioinformatics Institute (EMBL-EBI) & the UK QSP Network which is to be held 25th & 26th April 2022 in person at the EMBL-EBI Main Building, Hinxton, Cambridgeshire, UK
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
1. 25 Apr 2022 17:43 InSysBio's ASCPT 2022 Micro-Theater Session on YouTube InSysBio has published the videos of its presentation in frames of Micro-Theater Session at ASCPT 2022 Annual Meeting on InSysBio YouTube channel. Oleg Demin and Alexander Stepanov covered the topic of Online databases collecting and processing publicly available data that can help in calibration and validation of QSP models.
26
27
28
29
30
 
Upcoming Events
25.06
InSysBio to hold a workshop on IRT at PAGE 2024
Tags
Latest News
22.02
14th InSysBio’s Annual Internal Scientific Meeting
24.01
InSysBio to present the new Plugin for Sublime Text and Heta compiler Online
07.12
InSysBio to release public beta of fIVE Calculator
06.04
InSysBio to release Immune Response Template 3.6.2 for QSP modeling
16.01
InSysBio team to publish the new article “Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study”